CD40LG (CD40L, TNFSF5, CD154), one of the most well-studied TNFSF, has been a therapy target in cancer treatment and is typically associated with the prognosis of lung cancer (Mu et al., 2015). Here, CD40LG is linked to lung carcinoma.